A Phase 3 interventional study of Anidulafungin and Fluconazole in Candidiasis, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2008-10-21.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing anidulafungin in Candidemia — none open to participants now, none under way, none of them phase 3. Anidulafungin · Candidemia.
Among the 11 studies testing anidulafungin in Candidemia, this one is the 2nd largest by enrollment, is the only one that started in 2003, is one of 5 in phase 3, and was the 2nd registered.
73 studies on the registry are indexed under Candidemia; 5 are open to participants now.
Browse Candidemia studies →None of the 11 studies testing anidulafungin in Candidemia is open now. The open studies under Candidemia, anywhere →
Anidulafungin: first FDA approval 2006 (ERAXIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 2 Candidemia studies recruiting now, 2 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 1 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 256 is above the median of 63 across 44 interventional studies indexed under Candidemia.
Median enrollment 70 across the 11 interventional studies. Of the 11 that completed or were terminated, 9 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 11 have an industry lead sponsor. The 3 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
15 studies in Candidemia by Pfizer: none open now, none under way, none of them phase 3. Of 15 finished, 13 (87%) have results posted.
Among the 15 studies in Candidemia by Pfizer, this one is the 2nd largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2003, is one of 7 in phase 3, and was the 2nd registered.
Pfizer’s Candidemia studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing anidulafungin in Candidemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 15 in Candidemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Anidulafungin is a medicine being developed for treatment of patients with certain kinds of fungal infections. These infections due to yeast (a type of fungus) in the mouth/esophagus, in the blood or in other areas within the body.
Anidulafungin is an investigational drug being developed as an intravenous treatment for esophageal candidiasis, candidemia and other invasive fungal infections. Anidulafungin is an antifungal agent of the echinocandin class, which targets the fungal cell wall of yeast and other filamentous fungi.
73 studies on the registry are indexed under Candidemia; 5 are open to participants now.
This study's enrollment of 256 is above the median of 63 across 44 interventional studies indexed under Candidemia.
Browse Candidemia studies →Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Compared within Candidemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Candidiasis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The record gives a start of Mar 2003 and a completion of Oct 2004. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Anidulafungin · Fluconazole